Anika Therapeutics, Inc.

How big is Anika Therapeutics, Inc.?

As of Jun 18, Anika Therapeutics, Inc. has a market capitalization of 158.19 million and reported net sales of 137.44 million with a net profit of -36.46 million over the latest four quarters.

As of Jun 18, Anika Therapeutics, Inc. has a market capitalization of 158.19 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 137.44 million, while the sum of net profit for the same period is -36.46 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 153.99 million, and total assets amount to 215.63 million.

What does Anika Therapeutics, Inc. do?

Anika Therapeutics, Inc. is a joint preservation company specializing in early intervention orthopedic care, with recent net sales of $26 million and a market cap of $158.19 million. The company reported a net loss of $4 million and has a negative return on equity of -22.47%.

Overview:<BR>Anika Therapeutics, Inc. is a joint preservation company that focuses on advancements in early intervention orthopedic care within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 26 Million (Quarterly Results - Mar 2025)<BR>- Most recent Net Profit: -4 Million (Quarterly Results - Mar 2025)<BR>- Market-cap: USD 158.19 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.35<BR>- Return on Equity: -22.47%<BR>- Price to Book: 1.07<BR><BR>Contact Details:<BR>- Address: 32 Wiggins Ave, BEDFORD MA: 01730-2315<BR>- Tel: 1 781 4579000<BR>- Website: https://www.anikatherapeutics.com/

Should I buy, sell or hold Anika Therapeutics, Inc.?

Who are in the management team of Anika Therapeutics, Inc.?

As of March 2022, Anika Therapeutics, Inc.'s management team includes Dr. Joseph Bower as Independent Chairman and Dr. Cheryl Blanchard as President and CEO, along with several Independent Directors on the Board.

As of March 2022, the management team of Anika Therapeutics, Inc. includes the following individuals:<BR><BR>- Dr. Joseph Bower, who serves as the Independent Chairman of the Board.<BR>- Dr. Cheryl Blanchard, who is the President, Chief Executive Officer, and a Director.<BR><BR>Additionally, the Board of Directors features several Independent Directors: Mr. John Henneman, Mr. Raymond Land, Dr. Glenn Larsen, Mr. Stephen Richard, and Mr. Jeffery Thompson.

Is Anika Therapeutics, Inc. overvalued or undervalued?

As of May 5, 2022, Anika Therapeutics, Inc. is considered overvalued and risky due to negative earnings, poor financial metrics, and a year-to-date stock performance decline of 45.69%, significantly underperforming the S&P 500.

As of 5 May 2022, the valuation grade for Anika Therapeutics, Inc. has moved from attractive to risky, indicating a significant deterioration in its valuation outlook. The company appears to be overvalued given its current financial metrics, with a Price to Book Value of 1.10 and an EV to Sales ratio of 0.81, which are concerning in the context of its negative earnings and returns. Additionally, the EV to EBIT and EV to EBITDA ratios are both negative at -3.74 and -4.95, respectively, highlighting the company's struggles in generating profit.<BR><BR>In comparison to its peers, Anika Therapeutics has a less favorable valuation profile, with CareDx, Inc. rated very attractive with a P/E ratio of -27.91, while AngioDynamics, Inc. is also classified as risky with a P/E of -24.69. The company's recent stock performance has been poor, with a year-to-date return of -45.69%, significantly underperforming the S&P 500's positive return of 12.22% in the same period. This further reinforces the view that Anika Therapeutics is currently overvalued.

Is Anika Therapeutics, Inc. technically bullish or bearish?

As of August 15, 2025, Anika Therapeutics, Inc. shows a mildly bearish trend with mixed technical signals, underperforming the S&P 500 significantly with a year-to-date return of -45.69% compared to the S&P 500's 12.22%.

As of 15 August 2025, the technical trend for Anika Therapeutics, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD remains bearish, indicating mixed signals. The RSI shows no signal on the weekly chart but is bullish on the monthly chart. Bollinger Bands and moving averages are bearish on the daily timeframe, contributing to the overall mildly bearish stance. <BR><BR>In terms of performance, the stock has underperformed significantly compared to the S&P 500, with a year-to-date return of -45.69% versus the S&P 500's 12.22%, and a one-year return of -64.90% compared to the S&P 500's 17.14%.